相关实验视频

Updated: May 3, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

基于的[18F]siPSMA-14在前列腺癌患者中的首次临床应用:概念验证研究

Jonathan Miksch^1,2, Elham Yousefzadeh-Nowshahr¹, Deni Hardiansyah³

¹Nuclear Medicine, Ulm University Hospital, Ulm, Germany.

Nuklearmedizin. Nuclear medicine

|September 5, 2025

概括

新的[18F]siPSMA-14追踪器显示安全有效的前列腺癌成像. 这种基于的新药具有很高的病变吸收率和适度的有效剂量,简化了生产和使用,无需强制性尿液.

科学领域:

放射化学和核医学
癌症成像
医学物理

背景情况:

前列腺特异性膜抗原 (PSMA) 标记物对于前列腺癌 (PCa) 的分期至关重要.
基于的配体在PSMA标记剂的生产可扩展性方面具有优势.
评估像[18F]siPSMA-14这样的新型标记剂对于提高诊断准确性至关重要.

研究的目的:

评估新型PSMA特异性标记物[18F]siPSMA-14的剂量和生物分布.
评估[18F]siPSMA-14在PCa患者PET/CT成像中的安全性和有效性.
将[18F]siPSMA-14与现有的PSMA标记剂的性能进行比较.

主要方法:

在七名接受PSMA- PET/CT的PCa患者中进行剂量测量和生物分布研究.
在注射后60分钟和120分钟进行成像 (p. i.) 没有强迫的尿液.
对器官吸收剂量 (AD),有效剂量 (ED),SUVmax和目标与非目标比率 (TnTR) 的分析.

主要成果:

[18F]siPSMA-14显示中等有效剂量 (1.95E-02±0.25E-02 mSv/ MBq) 在脏中具有最高的AD.
随着时间的推移,在局部和转移性PCa病变中观察到强烈且显著增加的标记剂吸收.
在90分钟的时间里. 与之前和之后的时间点相比较,表明灵活性.

结论:

[18F]siPSMA-14表现出有利的剂量,与其他PSMA标记剂相比,即使没有强制性尿液.
在PCa病变中,其高且不断增加的标记物吸收支持其诊断潜力.
简单,可扩展的生产和证明的安全性和有效性使[18F]siPSMA-14成为PCa成像的一个有前途的工具.

更多相关视频

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

18F-Labeling of Radiotracers Functionalized with a Silicon Fluoride Acceptor SiFA for Positron Emission Tomography

Published on: January 11, 2020

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Automated Preparation of [⁶⁸Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

相关概念视频

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET